Wechseln Sie zum Testsieger und sichern Sie sich bis zu 4.000 € Prämie für Ihr Fondsdepot!-w-
01.12.2021 08:14

Eurocine Vaccines´ Chlamydia vaccine candidate elicits both antibody and T cell responses

Folgen
Werbung

STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- In the latest preclinical study, it was shown that intramuscular immunization with the Chlamydia vaccine candidate elicits an excellent T cell response, in addition to the previously confirmed antibody responses. Achieving this combination of antibodies and T cells indicates that our vaccine candidate generates an effective barrier, which can prevent infection as well as promote clearance of infected cells.

Our studies have to date shown that parenteral immunization generates much stronger antibody responses than mucosal immunization. The latest study shows that vaccination elicits CD4+ and CD8+ T cells capable of recognizing, and potentially also eradicating, Chlamydia-infected cells. In particular, the induction of interferon-gamma-producing CD4+ T cells is potent, and cytokine release profiles are consistent with Th1 responses. These are exactly the type of T cell responses that, along with antibodies, are considered to have the greatest potential to provide protection against chlamydia infection and subsequent complications.

Vaccines that generate T cells can be more effective than conventional antibody vaccines to protect against microbes, which hide inside host cells, as e.g. Chlamydia. The combination of antibodies and T cells thereby creates the conditions to both prevent infection and to cure an already established infection.

"We are very pleased by the strong confirmatory findings so far in this project and that we can induce exactly the type of immune response that is considered important for protection against Chlamydia infection", says Dr. Karl Ljungberg, Director of Preclinical Development.

Ongoing and planned activities to prepare for the first clinical study on Eurocine Vaccines' Chlamydia vaccine candidate, planned to begin by the end of 2022, include e.g. further preclinical development, development of an industrially scalable manufacturing process, toxicological testing and manufacture of study products according to GMP.

Read more about the candidate:

https://www.eurocine-vaccines.com/the-portfolio/

CONTACT:

Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com
+46 70 634 0171

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eurocine-vaccines/r/eurocine-vaccines--chlamydia-vaccine-candidate-elicits-both-antibody-and-t-cell-responses,c3463771

The following files are available for download:

https://mb.cision.com/Main/11552/3463771/1503884.pdf

Eurocine Vaccines´ Chlamydia vaccine candidate elicits both antibody and T cell responses

https://news.cision.com/eurocine-vaccines/i/ev-karl-squere-brickwall,c2986993

EV Karl Squere BrickWall

 

Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

DAX leichter -- Asiens Börsen uneinheitlich -- Siemens verkauft Yunex für fast eine Milliarde Euro -- AUTO1 mit Rekordverkäufen -- HUGO BOSS steigert EBIT kräftig -- CureVac im Fokus

Elon Musk kommt Mitte Februar erneut nach Deutschland. Lindt & Sprüngli legt bei Umsatz zu. US-Fluggesellschaften warnen vor Luftfahrt-Chaos durch 5G-Einführung. Covestro erwirbt restliche Anteile an Japan Fine Coatings. Nordex verzeichnet 2021 deutlich mehr Auftragseingänge. Daimler Truck steigert Absatz 2021 um ein Fünftel. EVOTEC und Eliy Lilly kooperieren bei Stoffwechselerkrankungen.

Umfrage

Haben Sie Verständnis für Menschen, die gegen die Corona-Politik demonstrieren?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln